echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > China has officially joined the implementation plan for the new crown pneumonia vaccine.

    China has officially joined the implementation plan for the new crown pneumonia vaccine.

    • Last Update: 2020-10-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On October 8, China signed an agreement with the Global Alliance for Vaccine Immunization to formally join the New Coronary Pneumonia Vaccine Implementation Program.
    public information, the New Coronary Pneumonia Vaccine Implementation Plan is a joint and led project by the Global Alliance for Vaccine Immunization (Gavi), the World Health Organization (WHO) and the Alliance for Innovation in Epidemiological Prevention (CEPI).
    aims to accelerate the development and production of new crown vaccines and ensure equitable access to new crown vaccines in every country.
    , nearly two-thirds of the world's population has joined the New Coronary Pneumonia Vaccine Implementation Program, according to data released by the World Health Organization on September 21.
    nine new crown vaccines are currently selected under the program, and several others are still being evaluated.
    October 8, China officially joined the "New Crown Pneumonia Vaccine Implementation Program".
    Spokeswoman Hua Chunying said that at present, the new crown epidemic is still in a global pandemic, seriously threatening the lives and health of people of all countries.
    ensuring equal access to suitable, safe and effective vaccines in developing countries is a priority for China.
    China solemnly promises that when China's vaccine research and development is completed and put into use, it will be made available to developing countries as a global public product.
    , China maintains close communication with the Implementation Plan and has a positive attitude towards joining the Implementation Plan.
    Although China has a leading international vaccine research and development and sufficient production capacity, we have decided to join the Implementation Plan with the aim of promoting equitable distribution of vaccines through practical actions to ensure that vaccines are available to developing countries, while at the same time driving more capable countries to join and support the Implementation Plan.
    china will also strengthen vaccine cooperation with relevant countries by joining the Implementation Plan.
    China will continue to work with all parties in the Implementation Plan to make China's contribution to global unity in the fight against the epidemic and to the protection of the lives and health of people from all over the world.
    , deputy director of the Institute of International Strategy at the China Institute of International Studies, said: "The plan is now in effect, and based on our previous observations, it should be said that more than 160 economies have joined."
    Now for China, we would prefer the big countries to join, because we will see that in the process of epidemic prevention and control, in the process of global epidemic control, there are individual big countries, especially the United States, its role is very negative.
    U.S. is eager to work with big vaccine companies, but mainly wants to secure its own vaccine supply, and there have been very negative attempts to monopolize vaccines.
    withdrawal of the United States from WHO, its participation in the Implementation Plan and its refusal to provide public products have had a negative impact on the fight against the epidemic in developing countries and on the global response to the epidemic.
    so China, through its own actions, we have taken the initiative to join, but also hope to drive more countries, especially large countries, to choose the right path.
    " Medical Valley.com Source: Medical Valley.com Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medical, and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.